Zonagen divests Fertility Technologies:
This article was originally published in Clinica
Executive Summary
Zonagen, a reproductive health, sexual dysfunction and urologic pharmaceuticals company has sold its wholly-owned Fertility Technologies to SAGE BioPharma. The Woodlands, Texas-based Fertility Technologies markets and distributes a number of diagnostics and devices involved in so-called assisted reproductive technique procedures. The terms of the sale were not disclosed, although Zonagen said that the subsidiary was sold as it did not represent Zonagen's core business of drug discovery.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.